In a recent regulatory filing with the SEC, Neonc Technologies Holdings, Inc. (NASDAQ: NTHI) disclosed that its President and Director, Amir F. Heshmatpour, has increased his position in the company through an open-market purchase. Mr. Heshmatpour, who also holds a ten percent ownership stake in the organization, acquired 10,000 shares of common stock on April 28, 2026.
The acquisition was completed at a price point of $4.518 per share, representing a total investment of $45,180. This transaction occurs against a backdrop of recent share price volatility for NTHI; the stock is currently trading at $4.31, reflecting a 16% decrease over the preceding week and an approximate 48% decline year-to-date.
Detailed Ownership Structure
Following this latest transaction, Mr. Heshmatpour's direct ownership in Neonc Technologies Holdings, Inc. stands at 3,062,000 shares. This total includes 275,000 shares held by specific members of his immediate family, though Mr. Heshmatpour disclaims beneficial ownership of those specific shares except to the extent of any pecuniary interest he may have.
The President's interest in the company is also reflected through several indirect holdings and various entities:
- AFH Holdings & Advisory, LLC: As the sole member and manager, Mr. Heshmatpour holds 3,714,020 shares indirectly through this entity.
- KIG LLC: He holds 550,000 shares via KIG LLC, an entity where his spouse is the sole member. He disclaims beneficial ownership here except for any pecuniary interest.
- HCWG LLC: He maintains a proportionate interest representing 256,120 shares through this LLC.
Corporate Developments and Clinical Outlook
The insider purchase follows several significant operational updates from Neonc Technologies. The company recently secured approximately $16 million in capital through a private placement involving a securities purchase agreement for the sale of common stock and warrants. This move was intended to bolster the company's operational liquidity.
On the research front, BTIG has initiated coverage on NTHI with a buy rating and a price target of $15.00. The analyst firm highlighted Neonc’s specific focus on developing drugs for central nervous system (CNS) tumors, specifically noting the company's application of Perillyl Alcohol to improve the delivery of anti-cancer agents to the CNS.
Furthermore, the company is preparing to present initial data from its NEO212-01 Phase 1/2 clinical trial regarding CNS malignancies during an upcoming investor conference call. This clinical progress is a central component of Neonc's ongoing activities within the biopharmaceutical sector.
Other recent corporate actions include the appointment of David Choi as Chief Accounting Officer to manage financial reporting and accounting functions, as well as the resolution of a legal dispute with Fox Infused, LLC. The settlement involving product supply and patent licensing resulted in a payment of $737,920.77 from Neonc Technologies.
Key Market Points
- Insider Confidence: The acquisition of 10,000 shares by the President and a significant owner suggests an internal valuation perspective that differs from the recent 48% year-to-date decline in stock price.
- Capitalization and Liquidity: The successful $16 million private placement provides the company with necessary capital to continue its biopharmaceutical operations.
- Clinical Inflection Points: The upcoming presentation of NEO212-01 Phase 1/2 clinical trial data represents a potential milestone for the company's CNS tumor drug pipeline.
Risks and Uncertainties
- Market Volatility: The recent 16% weekly drop and 48% year-to-date decline in NTHI shares highlight significant volatility in the biotechnology sector and for this specific ticker.
- Clinical Trial Outcomes: As a biopharmaceutical entity, the company's progress is tied to the results of clinical trials like the NEO212-01 study, which carry inherent scientific uncertainties.
- Legal and Financial Obligations: Recent settlements, such as the $737,920.77 payment to Fox Infused, LLC, represent cash outflows that impact the company's financial position.